Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | PSMB8 | P28062 | 12/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25992588 | 0.76 | OGT (0.59) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL29747565 | 0.76 | KDM4E (1.00) | KDM4EGAAMEN1MAPTKMT2A | |
| SCHEMBL4699050 | 0.76 | KDM4E (1.00) | KDM4EGAAMEN1MAPTKMT2A | |
| SCHEMBL4703352 | 0.76 | KDM4E (0.75) | KDM4EGAAMEN1MAPTKMT2A | |
| SCHEMBL12716526 | 0.75 | KDM4E (0.82) | KDM4EGAAMEN1MAPTKMT2A | |
| SCHEMBL7565625 | 0.74 | ALDH1A1 (0.47) | KDM4EGAAMEN1MAPTKMT2A | |
| SCHEMBL30834681 | 0.74 | PSMB8 (1.00) | KDM4EGAAMEN1MAPTKMT2A | |
| SCHEMBL97140 | 0.74 | PSMB8 (1.00) | KDM4EGAAMEN1MAPTKMT2A | |
| Benzo[D]Isoxazole SCHEMBL27740685 | 0.71 | PSMB8 (0.66) | KDM4EGAAMEN1MAPTKMT2A | |
| SCHEMBL10897160 | 0.69 | PSMB8 (0.63) | KDM4EGAAMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439236-B2 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1219622-B1 | Pharmaceutical compositions for CNS and other disorders | PFIZER PROD INC (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070099904-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
| US-6881734-B2 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-6809094-B2 | N-FUSED HETERCYCLO-1,4- OR -1,5- DIAZABICYCLO DERIVATIVES; NICOTINIC RECEPTOR AGONISTS; CENTRAL NERVOUS SYSTEM (CNS) | PFIZER INC | 2004-10-26 | — | — | US | disclosed |
| US-20040204416-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| US-20030119837-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. | 2003-06-26 | — | — | US | disclosed |
| US-20020086871-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | O'NEILL BRIAN THOMAS (US) | 2002-07-04 | — | — | US | disclosed |
| EP-1219622-A2 | Pharmaceutical compositions for CNS and other disorders | Pfizer Products Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA10, CHRNA5 | KDM4E 4027/4885GAA 491/4885MEN1 1569/4885 |
| US-20030119837-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | KDM4E 4365/4885GAA 676/4885MEN1 1195/4885 |
| US-20020086871-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | KDM4E 4365/4885GAA 676/4885MEN1 1195/4885 |
| US-20070099904-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS | C1QBP, BCHE, BDNF | KDM4E 1393/4885GAA 1255/4885MEN1 2027/4885 |
| US-20040204416-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | KDM4E 4365/4885GAA 676/4885MEN1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.